NYSEAMERICAN:OSTX

OS Therapies Q3 2026 Earnings Results & Report

OS Therapies logo
$0.80 -0.02 (-2.12%)
Closing price 11/20/2026 04:10 PM Eastern
Extended Trading
$0.81 +0.01 (+0.87%)
As of 11/20/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OS Therapies missed analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.23 versus the -$0.13 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
7:00 AM ET

OS Therapies EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

OS Therapies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

OS Therapies Q3 2026 Earnings FAQ

OS Therapies (NYSEAMERICAN:OSTX) reported earnings of -$0.23 per share for Q3 2026, missing the consensus estimate of -$0.13. The report was announced on Monday, November 16, 2026.

OS Therapies Earnings Headlines

OS Therapies (NYSEAMERICAN:OSTX) Shares Climb 9.4% - Still a Buy?
OS Therapies Notes FDA CNPV Program Suspension
A $247 tool for $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
See More OS Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OS Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OS Therapies and other key companies, straight to your email.

About OS Therapies

OS Therapies (NYSEAMERICAN:OSTX) is a clinical-stage biotechnology company focused on developing treatments for osteosarcoma, a rare bone cancer, and potentially other cancers. Its work centers on therapies intended to address the significant risk of recurrence and spread associated with the disease.

The company’s lead candidate, OST-HER2, is an investigational immunotherapy designed to stimulate an immune response against HER2-expressing cancer cells. OS Therapies has studied it for osteosarcoma, including disease that has spread to the lungs. OST-HER2 remains an investigational product and is not an approved treatment.

OS Therapies also describes a broader development effort aimed at advancing treatments for osteosarcoma and other solid tumors. Its activities include clinical development and research into therapies for cancers with limited treatment options.

View OS Therapies Profile